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Objective. The nuclear interferon-inducible protein 16 (IFI16) and anti-IFI16 antibodies 
have been detected in subjects with several rheumatic diseases, often correlating with 
disease severity, and we herein investigated their prevalence and clinical associations in 
psoriatic arthritis (PsA) compared to psoriasis (Pso). 
Methods. We tested sera and synovial fluids of patients with PsA for IFI16 protein 
levels by capture ELISA and for anti-IFI16 IgG and IgA by ELISA, protein radio-
immunoprecipitation and immunoprecipitation-Western blot of IgG. Sera from patients 
with Pso and healthy subjects were used as controls, and in a subgroup of patients with 
PsA we also studied sera after treatment with etanercept. 
Results. IFI16 was detectable in the sera of 66% of patients with Pso, 46% of PsA, and 
19% of controls. Among PsA cases, 51% of IFI16-positive cases had elevated levels of 
C-reactive protein (CRP) compared to 31% of patients with undetectable IFI16. Anti-
IFI16 of both IgG and IgA isoforms were detected with significantly higher frequency 
in PsA and Pso compared to healthy controls, with higher IgG titers in patients with 
elevated CRP (p=0.015) and a significant reduction in the majority of patients after 3 
month of etanercept treatment. Immunoprecipitation confirmed the presence of anti-
IFI16 IgG antibodies and these recognized the HINA epitope predominantly (amino 
acids 131 to 337). Lastly, IFI16 was detected in 1/7 and anti-IFI16 in 3/7 synovial fluids 
from patients with PsA. 
Conclusion. IFI16 and anti-IFI16 seem to be associated with higher disease activity and 
with treatment response in PsA. The detectability of these markers also in synovial 
fluids represents a novel finding with potential clinical implications.































































Psoriatic arthritis (PsA) is a chronic inflammatory disease within the broader psoriatic 
disease encompassing musculoskeletal features (with enthesitis, synovitis and erosion 
with osteitis of the peripheral joints and/or the axial skeleton), skin and nail 
manifestations [1], estimated to affect approximately 0.5% of the general population [2]. 
PsA is found in a variable proportion (15-40%) of the patients with psoriasis (Pso), and 
in 74% of cases it is preceded by skin manifestations [3]. 
Different from rheumatoid arthritis (RA), both PsA and Pso lack serum biomarkers for 
an early diagnosis, while sharing a T cell-mediated response based on the tumor 
necrosis factor-α (TNF-α)/interleukin(IL)-17 axis [4]. As reported for other immune-
mediated diseases [5], an interferon (IFN) signature is observed in Pso as self-DNA-
engulfed plasmacytoid dendritic cells (pDC) produce a large amount of IFN-α [6]. 
Further, an overexpression of IFN-γ and TNF-α-inducible genes is observed in Pso 
plaques due to T cell and macrophage recruitment and activation [7]. Despite these 
observations, treatments targeting IFN-α or IFN-γ have proven ineffective in Pso, while 
TNF-α and IL12/23 or IL17 blockers lead to clear skin in a large proportion of patients 
[8, 9]. 
The interferon-inducible protein 16 (IFI16) is a  DNA sensor involved in the 
inflammasome-mediated defense against viral infections [10], that displays also pro-
inflammatory and anti-angiogenetic effects [11]. In the case of psoriatic disease, IFI16 
is overexpressed in the affected skin [12], in peripheral blood mononuclear cells, and 
synovial tissues [13, 14]. Previous studies have demonstrated that IFI16 is 
overexpressed in different connective tissue diseases and in RA [5], and anti-IFI16 
antibodies have been detected in systemic lupus erythematosus (SLE) [15], Sjӧgren’s 































































syndrome [16, 17], systemic sclerosis [18-20], inflammatory bowel diseases [21], and 
RA [22], possibly associated with disease severity and progression. 
We report herein for the first time that IFI16 and anti-IFI16 antibodies are detectable in 
the sera and synovial fluids of patients with PsA and may represent disease activity 
biomarkers.

































































We investigated 158 consecutive patients with a diagnosis of PsA based on the 
CASPAR criteria [23] (Table 1), while 182 healthy subjects and 44 patients with skin 
or nail Pso but no evidence of PsA were used as controls. Serum samples were collected 
and stored at − 20°C until used; demographic and clinical data (presence or absence of 
psoriasis, presence or absence of axial involvement and reported blood tests done by the 
patient within one month) were recorded. DAS28 (disease activity score 28 joint) was 
available only for 30 PsA patients treated with biologic agents.  
In a subgroup of 8 patients with PsA, serum samples were also available at 3 months 
after starting weekly subcutaneously etanercept 50 mg. Synovial fluid samples from 7 
patients with PsA who underwent arthrocentesis for knee effusion and had not received 
intra-articular medications (e.g., corticosteroids, hyaluronic acid) in the previous 6 
months, were also analyzed (blood samples were collected on the same day). Synovial 
fluids were centrifuged and supernatants stored at − 80°C until use. Clinical and 
serologic records were collected at the time of enrollment. This study was approved by 
the local IRB and written informed consents were obtained from patients and controls.
Determination of extracellular IFI16 protein by capture ELISA 
A capture ELISA was employed for determination of circulating extracellular IFI16 
protein following a procedure described elsewhere [24], and the threshold cut-off value 
was defined as the 95th percentile of healthy controls as 27 ng/ml.
Determination of antibody titers toward human recombinant IFI16 by ELISA
To determine anti-IFI16 antibody titers of IgG and IgA isotype in sera of patients, we 































































performed in-house ELISA as previously described [21]. Accordingly, cut-off values 
were calculated as the 95th percentile of healthy controls and the threshold values were 
set to 113 U/ml and 9.6 U/ml for IgG and IgA isotype, respectively.
Indirect immunofluorescence assay
The localization of cellular antigens recognized by autoantibodies was tested by indirect 
immunofluorescence (IIF) on HEp-2 cells (INOVA Diagnostics, San Diego, CA, USA) 
using a 1:80 dilution of human sera of patients and controls, followed by secondary 
antibodies marked with fluorochrome (AlexaFluor488 AffiniPure F(ab')2 fragment goat 
anti-human IgG, Fcγ fragment specific, Jackson Immunoresearch Europe Ltd, Suffolk, 
UK) as previously described [25]. Samples were acquired on Olympus BX53 Upright 
fluorescence microscope.
Radioimmunoprecipitation assay
PsA sera were analyzed by protein radio-immunoprecipitation (IP) using marked 35S- 
HeLa cell extract. IP was used to identify autoantibodies directed against protein self-
antigens as described elsewhere [26]; briefly, sera were incubated with Protein A 
sepharose (PAS) beads and after serial washes samples have been incubated with cell 
lysate (radioactively marked for protein-IP). After forming immuno-complexes, 
samples were prepared for 8% sodium dodecyl sulphate- polyacrylamide (SDS-PAGE) 
electrophoresis for protein-IP. To confirm data obtained with IP we performed IP-
Western blotting. In detail, human sera and 50ng of mouse monoclonal anti-human 
IFI16 as a positive control were cross-linked with PAS beads to isolate human IgG 
directed against IFI16 [27]. IP was initially performed with cell extract from 5x106 
HeLa cells/sample, but since human foreskin fibroblast (HFF) express IFI16 at higher 































































basal levels than HeLa, control experiment was performed with HFF. Proteins were 
then fractionated by 8% SDS-PAGE and transferred to a nitrocellulose membrane, 
probed with 1:500 of mouse monoclonal anti-human IFI16 antibody (Novus 
Biologicals, Littleton, CO, USA) for band 88 kDa identification, followed by 
horseradish peroxidase (HRP)-goat anti-mouse IgG (1: 10000 dilution; ThermoFisher, 
Waltham, MA, USA). Development was performed by Immobilon Western 
Chemiluminescent HRP substrate (Millipore, Darmstadt, Germany) and acquired using 
ChemiDoc (Bio-Rad, California, USA).
Recombinant IFI16 domains
The coding region of the three IFI16 domains was amplified from full length human 
IFI16 (isoform b) cDNA using primers containing BamHI and XhoI restriction sites 
(DAPIN: Fw 5’ GGCGGATCCATGGGAAAAAAATACAAGAAC 3’; Rw 5’ 
GCCTCGAGTCATTTTAACTTTTCTTTTTTAAG 3’; HIN A: Fw 5’ 
GGCGGATCCCCGAAAACAGTGGCCAAATG 3’; Rw 5’ 
GCCTCGAGTCATTTCTTTATCTGGATAAAACTA 3’; HIN B: Fw 5’ 
GGCGGATCCGAACCTGAAGAAGTTTCCATA 3’; Rw 5’ 
GCCTCGAGTCAGATGACCTTGATGTGACTATG 3’). The amplified inserts were 
digested with BamHI and XhoI, and cloned in pET30a expression vector containing an 
N-terminal histidine tag (Novagen, Madison, WI). Expression and affinity purification 
of the recombinant proteins were performed according to standard procedures, and 
purity assessed by 12% SDS-PAGE gel electrophoresis.
IFI16 epitope mapping































































IFI16 protein domains were diluted in phosphate buffered saline (PBS) to a 
concentration of 2 ug/ml. Polystyrene microwell plates (Nunc-Immuno Maxisorp) 
(Thermo Scientific, Nunc, Roskilde, Denmark) were coated with 100 µl diluted protein 
per well, and incubated overnight at 4°C. After blocking, sera were added in duplicate. 
After washing, horseradish peroxidase-conjugated rabbit anti-human IgG 
(DakoCytomation) was added. Following the addition of the substrate 
(tetramethylbenzidine, KPL), absorbance was measured at 450 nm using a microplate 
reader (SpectraCount,Packard BioScience). The background reactivity of the reference 
mixture was subtracted to calculate the results. 
Statistical analysis
All data analyses were performed using Stata for Macintosh 13.1 (StataCorp, College 
Station, Tx, USA). As detailed throughout, chi-square test, Mann-Whitney U test, 
Kruskal-Wallis test with Dunn's test for multiple comparison post hoc, or Wilcoxon test 
were employed to compare groups based on the data distribution. Linear regression and 
Spearman’s test were used to correlate IFI16 and anti-IFI16 levels with continuous 
variables such as disease duration and age. C reactive protein (CRP) levels were 
reported for patients who had available blood tests within one months, the absolute 
values were not comparable due to different cut-offs between laboratories, therefore, we 
used the single cut-off of each center to discriminate high CRP levels.   
 Multivariate analysis adjusted for demographic and clinical data (age, sex and disease 
duration) was also performed. All comparisons were two-tailed and P values below 0.05 
were considered statistically significant.
































































Circulating IFI16 in different disease groups.
The levels of IFI16 were significantly higher in PsA and Pso patients compared to 
healthy controls (PsA median 0, range 0-131 versus healthy controls 0, 0-67.6, 
p=0.0004; Pso 7.93, 0-223.5 versus healthy controls p<0.0001; figure 1A). Moreover, 
IFI16 concentrations were higher in Pso patients compared to PsA (p=0.0006). 
According to the established 27 ng/ml threshold, 23/158 (15%) of PsA and 8/44 (18%) 
Pso sera were positive for circulating IFI16, compared to 6/116 (5%) healthy controls 
(PsA versus healthy controls p=0.002; Pso versus healthy controls p=0.003), confirming 
a higher prevalence of free IFI16 circulating protein in PsA and Pso patients in 
comparison with healthy controls.
Circulating IFI16 and PsA clinical features at baseline.
The clinical features of the PsA cases included disease duration, peripheral or axial 
involvement, and skin disease were analyzed according to the positivity/negativity for 
IFI16 protein are illustrated in Table 1. We identified a significant association between 
elevated CRP levels and the presence of the circulating IFI16 protein (p<0.0001). We 
subsequently evaluated whether IFI16 serum concentration, rather than its presence, 
could be correlated to any clinical variable. As expected, IFI16 levels were significantly 
higher in PsA cases with high CRP levels (median 23.5ng/mL, interquartile range (IQR) 
10.4-65.4) compared with patients with low CRP levels (2.6 ng/mL, IQR 1.4-10.6; 
p<0.001). IFI16 levels were also higher in PsA cases with Pso compared with patients 
without skin disease, albeit not significantly (11.4 ng/ml, IQR 2.6-31.9 vs. 6.4 ng/ml, 
IQR 1.8-67.6). No differences in IFI16 levels were observed with regard to ongoing 































































therapies. We further performed a multivariate analysis with pre-specified confounders 
and this failed to identify statistically significant differences after adjustment for age, sex 
and disease duration. 
Circulating IFI16 and PsA response to etanercept.
Samples at 3 months of etanercept treatment were also available for 8 subjects positive 
for IFI16 at baseline and we could observe a decrease in IFI16 levels in 5/8 patients 
(baseline median 81.7 ng/ml, IQR 63.2-102.1 vs. 31.8 ng/ml, 22.1-85 at 3 months; 
p=0.16). Similarly, according to DAS28-CRP, disease activity reached a minimal 
clinically significant reduction in 4/8 IFI16 positive patients, with a median reduction of 
1.25 points. Lastly, circulating IFI16 was measured in the synovial fluid of 7 PsA 
patients and detected in one case at low concentration (data not shown).
Circulating anti-IFI16 IgG and IgA and PsA clinical features at baseline.
Significantly higher levels of anti-IFI16 IgG antibodies were present in PsA and Pso 
patients in comparison with healthy controls (PsA median 96, IQR 65.3-151.7 versus 
healthy controls 28.9, IQR 17.3-45.3, p<0.001; Pso 94.9, 62.8-126 versus healthy 
controls, p<0.001), while the titers were comparable between PsA and Pso sera. 
According to the cut-off value of 113 U/ml, 57/158 (36%) PsA and 14/44 (32%) Pso 
sera were positive for anti-IFI16 IgG, compared to 11/182 (6%) of the healthy controls 
(p<0,001 versus PsA; p<0.001 versus Pso; Figure 1B).
When the autoantibody status was analyzed according to sex, age, disease duration, 
skin, axial involvement, or ongoing therapy (Table 1), we observed a significant 
correlation between anti-IFI16 IgG levels and disease duration after adjusting for age 































































(beta coefficient 0.38; p=0.036). Moreover, by considering anti-IFI16 IgG serum 
concentrations, anti-IFI16 IgG titers were increased in subjects with high CRP levels 
compared with subjects with low CRP levels (median 268.1 U/ml, IQR 162.8-562.4 
versus 162 U/ml, 142.1-199.7; p=0.015). However, there were no differences in the 
percentage of patients with high CRP and anti-IFI16 positive versus negative subjects 
(Table 1).  
Circulating anti-IFI16 IgG and IgA in different disease groups.
Median anti-IFI16 IgA titers were increased in PsA and Pso sera compared to healthy 
controls (PsA 4.7, IQR 3.3-7.1 versus healthy controls 3.7, 2.5-5.2, p<0.0001; Pso 7.4, 
0-16.5 versus healthy controls p<0.0001); moreover, anti-IFI16 IgA were higher in Pso 
compared to PsA sera (p<0.0001). According to the 9.6 U/ml threshold, 25/158 (16%) 
of PsA and 16/44 (36%) of Pso sera were positive, compared to 7/138 (5%) of healthy 
controls (p<0.001 versus PsA; p<0.001 versus Pso; p=0.004 PsA versus Pso) (Figure 
1C). As reported in Table 1, anti-IFI16 IgA positive PsA cases were significantly older 
compared to anti-IFI16 IgA negative (median age 63.5, IQR 49-69 vs 48.5, IQR 42-58; 
p<0.001).  
Circulating anti-IFI16 IgG and IgA and PsA response to etanercept.
Six subjects positive for anti-IFI16 IgG at baseline were tested also during etanercept 
therapy without significant changes in autoantibody titers after 3 months of therapy 
(baseline median 197 U/ml, IQR 188-269 versus 3months 223 U/ml, 194-269; p=0.9). 
Of these, 4/6 (67%) did not reach a minimal clinically significant reduction of DAS28-
CRP and the median DAS28 change was -0.85 after 3 months of therapy. Four subjects 































































positive for anti-IFI16 IgA were subsequently tested after 3 months of etanercept 
therapy without significant changes in antibody titers (basal median 7.56, IQR 5.18, 
12.72 versus 3 months 6.55, 5.46-12.6; p=0.2), while 3/4 (75%) of these reached a 
minimal clinically significant reduction of DAS28, with a median DAS28 change of -
2.25 (data not shown). 
Synovial fluid anti-IFI16 IgG and IgA and PsA clinical features.
Anti-IFI16 IgG and IgA antibodies were measured also in synovial fluids of 7 PsA 
patients (data not shown). Three out of 7 samples were positive for IgG subtype and 2/7 
were positive for IgA subtype, and only 1 patient was positive for both Ig subtypes. We 
failed to detect correlation between antibody titers and any of the clinical parameters 
analyzed. 
Anti-IFI16 confirmation tests
Protein-IP and IP-WB were used to confirm the presence of anti-IFI16 IgG antibodies, 
as these techniques are considered the gold standard for the identification of 
autoantibodies thanks to their high sensitivity and specificity. As shown in Figure 2A, 
we performed protein-IP on 19 cases and we identified an IP pattern of PsA sera 
recognizing a 90 kDa protein (black arrows, Figure 2A). This band corresponds to the 
IFI16 protein as shown by IP-WB (Figure 2B). IIF was also performed to localize the 
IFI16 antigenic target, and we could confirm it is present in the nucleus according the 
its nuclear function (Figure 2C).  
Circulating IFI16 and anti-IFI16 IgG and IgA in the study populations.































































When IFI16 and anti-IFI16 data were combined, no correlations were found between 
IFI16 and anti-IFI16 IgG or IgA levels. However, we note that among the 57 PsA 
patients positive for anti-IFI16 IgG, 13 (23%) were positive also for circulating IFI16. 
In contrast, 57% of the 23 patients positive for IFI16 were also positive for IgG 
autoantibodies (Table 2). Among the 25 PsA patients positive for anti-IFI16 IgA, 5 
(20%) were positive for the circulating protein. A significant correlation between anti-
IFI16 IgG and IgA antibody titers was observed in PsA (Spearman’s r=0.1802, 
p=0.0235). Moreover, while only 21% of the 57 PsA patients positive for anti-IFI16 
IgG were positive also for the IgA subtype, 48% of 25 IgA positive patients displayed 
also high titers of anti-IFI16 IgG antibodies.
 Anti-IFI16 IgG epitope mapping
To determine whether anti-IFI16 IgG antibodies detected in sera were directed against 
specific IFI16 domains, we cloned the DAPIN (spanning from aa 1 to 88), HINA (from 
aa 131 to 337) and HINB (from aa 506 to 705) domains of IFI16 in a pET30a 
expression vector. The purity and specificity of the recombinant domains were then 
established by blue Comassie and Western blot analyses, and finally recombinant 
DAPIN (rDAPIN), rHINA and rHINB were used as immobilized surface in ELISA for 
testing the sera of the 57 patients positive for anti-IFI16 IgG. As shown in Figure 3, the 
serum samples displayed a strong reactivity against the HIN domains. Regardless of 
their aminoacid homology (44%), HINA was better recognized in comparison with 
HINB domain by disease and control sera. In contrast, the DAPIN domain, which is the 
moiety of the protein mainly involved in inflammatory activity, was poorly detected by 































































autoantibodies, suggesting that anti-IFI16 IgGs are mainly directed against an epitope 
outside the N-terminus of the protein. 
































































A significant role of DNA sensing peptides in the pathogenesis of Pso has been recently 
suggested, largely based on data about LL37, a fragment of the anti-microbial protein 
cathelicidin, capable to activate dendritic cells by complexing self-DNA, and T cells by 
acting as a self-antigen [28, 29]. Similar to other autoimmune diseases characterized by 
serum reactivity to intracellular antigens we cannot speculate on the pathogenetic 
mechanisms linking IFI16 autoantibodies to tissue damage. However, we suggest that 
the DNA sensor IFI16 is involved as a self-antigen in the humoral response and in the 
inflammatory response possibly via the inflammasome in PsA. 
In the present study, we observed that IFI16 and anti-IFI16 seem to be associated with 
higher disease activity in PsA and possibly with response to anti-TNFalpha treatment, 
thus possibly being candidate biomarkers of this seronegative condition and 
representing a different clinical phenotype. Furthermore, these markers are detected also 
in the synovial fluids for the first time and may thus represent a mechanistic player in 
the PsA pathogenesis. These findings may be promising in filling the diagnostic gap of 
PsA where no serum biomarker for the diagnosis or management is available [30].
IFI16 is an interferon-induced protein and a DNA sensor able to start an innate immune 
response against pathogenic microorganism by activating the inflammasome and the 
production of type I IFNs [31]. It has been proposed that the large amount of self-DNA 
secondary to keratinocyte proliferation in Pso plaques can activate pDC via LL37/TLR9 
to produce INF-α and recruit T cells and, at the same time, can activate the 
inflammasome with IL-1β production [31, 32]. The overexpression of IFI16 in 
keratinocytes could be explained by an attempt to control excessive cell proliferation, 
resulting, however, in a chronic activation of the inflammasome. Furthermore, 































































extracellular IFI16 can spread inflammation since it has been demonstrated that the 
protein is able to bind the membrane of endothelial cells and to induce the production of 
pro-inflammatory cytokines in these cells [24, 33]. The hypothesis based on an 
accelerated cell turnover seems to be supported by the high IFI16 levels observed in 
patients with Pso and in PsA with skin PsO and IFI16 overexpression in PsA circulating 
mononuclear cells and synovial tissue [13]. In fact, in PsA sera IFI16 is significantly 
higher compared to healthy controls, particularly when associated with an active disease 
represented by elevated CRP and mechanisms may include changes similar to what 
observed in systemic lupus erythematosus models [34] or NETosis in a self-
perpetuating fashion [35]. 
Type I IFN inducible genes are elevated in the serum of patients with different systemic 
autoimmune diseases, albeit with inconclusive evidence and frequently conflicting 
results in different rheumatic conditions [36]. IFI16 is among the five most important 
IFN inducible genes being overexpressed in connective tissue diseases and RA, raising 
the coined “IFN-signature” [5]. Different from PsA in which IFI16 significantly 
correlates with inflammation, this protein is not a biomarker of disease activity in RA, 
but is associated with pulmonary involvement and with the presence of rheumatoid 
factor and anti-cyclic citrullinated peptide antibodies. IFI16 in RA synovial fluid is not 
associated with joint disease activity, disease duration or erosion [22]. In the case of 
SLE, IFI16 is associated with disease activity, particularly lupus nephritis, and is found 
overexpressed in skin lesions [18, 37, 38]. 
The inflammatory context in which an intracellular protein is released is thought to be 
one of the mechanisms leading to the breakdown of tolerance and the recognition of 
self-antigens; this hypothesis could explain the antibody response against IFI16 































































observed in PsA and Pso, particularly with the intriguing observation of a prevalent IgA 
response compared to IgG response in PsO versus PsA. As previously mentioned and 
different from PsA (with anti-IFI16 IgG titers slightly increased in subjects with 
elevated CRP levels), anti-IFI16 antibodies are not correlated to RA activity, but rather 
with serum autoantibody positivity, while no association between anti-IFI16 and disease 
activity or erosions has been found [22]. In SLE, anti-IFI16 antibodies were first 
reported to be associated with anti-double stranded DNA antibodies [17, 18], but this 
was not confirmed by our group [15]. Anti-IFI16 antibodies positive patients with 
systemic sclerosis were more likely to have limited cutaneous systemic sclerosis, a 
longer disease duration and more severe vascular and pulmonary manifestations, i.e. 
digital ischemia and a low carbon monoxide diffusing capacity [18, 20]. An association 
with disease severity, as for PsA, has been documented in Sjӧgren’s syndrome, with 
lower tear and saliva production, higher focus score in minor salivary glands biopsies, 
germinal center-like structures in the labial salivary gland lymphocytic infiltrates, and 
higher IgG and antinuclear antibodies levels being associated with anti-IFI16 [16, 17]. 
The epitope mapping also provided somehow surprising evidence compared to other 
rheumatic conditions. In systemic sclerosis, anti-IFI16 reacted with either N- or C-
terminal fragments or both [18], while in 70% of Sjӧgren’s syndrome anti-IFI16 were 
directed against an epitope outside the N terminus [17] and in SLE antibodies are 
directed predominantly against N-terminus [17]. We can hypothesize that in SLE anti-
IFI16 blocking the N-terminus allows the formation of self-DNA/IFI16 complexes 
which favor nucleic acid clearance and are protective in terms of SLE nephritis. Our 
data in PsA are in agreement with those obtained in Sjӧgren’s syndrome, since the 































































DAPIN domain was poorly detected by anti-IFI16 IgG. Accordingly, this would have 
left free the moiety of the protein mainly involved in the inflammatory activity.
We are well aware of the limitations of our study, including the limited clinical data 
available but we report for the first time that IFI16 and anti-IFI16 are detectable in the 
sera of patients with PsA and seems to correlate with the degree of inflammation and 
possibly with treatment response. We cannot exclude a role of this protein and the 
elicited antibody in the pathogenesis of PsA; moreover, IFI16 and anti-IFI16 maybe 
represent new candidate biomarkers for PsA diagnosis and monitoring when data 
confirmed in larger and longitudinal studies. 
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Figure 1. Serum IFI16 and anti-IFI16 IgG and IgA levels in patients with PsA, 
Psoriasis and HCs. (A) IFI16 protein levels in patients’ and controls’ sera were 
determined using an in-house capture ELISA. Each dot represents the concentration of 
IFI16 protein (expressed in ng/ml on a linear scale) in each individual subject. The 
horizontal bar represents the median values. Values over the dotted line indicate the 
percentage of subjects with IFI16 protein levels above the cut-off value (27 ng/ml). (B) 
Serum IgG and (C) IgA specific for IFI16 were quantified by ELISA in HC and patients 
suffering from psoriatic arthritis and psoriasis. Each dot represents the autoantibody 
level for each subject sample expressed in arbitrary units on a linear scale. The 
horizontal bars in each group represent the median values. Values over the dotted line 
indicate the percentage of subjects with antibody titers above the cutoff value (113 
U/mL for anti-IFI16 IgG and 9.6 U/mL for anti-IFI16 IgA, calculated as the 95th 
percentile of the control population). Statistical significance: ***p < 0.0001 (Mann–
Whitney tests).
Figure 2. Analysis of protein component of autoantigen IFI16 (8% SDS-PAGE) by 
radio-immunoprecipitation (IP) (A) and IP-Western Blotting (WB) (B), and 
indirect immunofluorescence (C). The IP pattern of PsA sera recognizing a 90 kDa 
protein (black arrows, 2A). IP-WB confirming the identity of the IP bands 
corresponding to IFI16 (2B). The expected ANA pattern for a representative sample 
positive for ani-IFI16 IgG (2C).































































Figure 3. Epitope mapping for anti-IFI16 IgG. To determine the target of the anti-
IFI16 IgG antibodies found in the sera of PsA patients, the DAPIN (spanning from aa 1 
to 88), HINA (from aa 131 to 337) and HINB (from aa 506 to 705) domains of IFI16 
were purified as recombinant peptides and 2ug/mL each used to perform ELISA. Each 
dot represents the value of the absorbance at 450nm for the 57 sera tested against the 
three domains. The horizontal bars in each group represent the median values. Statistical 
significance: ***p < 0.0001 (Mann–Whitney tests). Panel A shows PsA patients and 
panel B healthy controls.
































































Table 1. Demographic, clinical and serological characteristics of PsA patients.
 
 IFI16 Anti-IFI16 IgG Anti-IFI16 IgA
All PsA Positive Negative Positive Negative Positive Negative
Patients (%) 158 (100) 23 (15) 135 (85) 57 (36) 101 (64) 26 (17) 132 (83)
Women (%) 93 (50.5) 12 (52) 67 (50) 34 (60) 45 (45) 11 (42) 68 (52)























76 (49) 14 (61) 62 (47) 33 (60) 43 (43) 14 (54) 62 (47)




45 (29) 7 (30) 38 (29) 16 (28) 29 (29) 4 (15) 41 (31)
High CRP (%) 63 (40) 18 (78) 45 (33)* 23 (40) 40 (40) 12 (46) 51 (39)
Ongoing 
treatments:
no treatment 64 (40.5) 17 (74) 77 (57) 21 (39) 43 (43) 9 (35) 55 (42)





















anti-TNFα 30 (19) 2 (9) 28 (21) 15 (26) 15 (15) 3 (12) 27 (20)
etanercept 8 1 7 4 4 1 7
adalimumab 2 0 2 1 1 0 2
infliximab 20 1 19 9 11 2 18
Continuous variables are expressed as median and IQR, binary as numbers and percentages. 
PsA: psoriatic arthritis; IFI16: interferon-inducible protein 16; Ig: immunoglobulin; yy: years; mm: 
months; Ig: immunoglobulin; CRP: C reactive protein; TNF: tumor necrosis factor. 
*p<0.01 positive vs. negative patients, ** p<0.001 positive vs. negative patients 































































Table 2. Association of IFI16-based biomarkers in the PsA cohort.

















5/23 (22%) 12/57 (21%) -
Variables are expressed as numbers (n) and percentages. 
PsA: psoriatic arthritis; IFI16: interferon-inducible protein 16; Ig: immunoglobulin.
 *p<0.01, ** p<0.001































































Serum IFI16 and anti-IFI16 antibodies in psoriatic arthritis: possible correlation 
with disease activity and response to therapy
Short title: IFI16 and psoriatic arthritis
Marco De Andrea1,2,3*, Maria De Santis4*, Valeria Caneparo1,2,3, Elena Generali4, 
Silvia Sirotti4, Natasa Isailovic4, Giacomo Maria Guidelli4, Angela Ceribelli4, 
Marta Fabbroni5, Antonella Simpatico5, Luca Cantarini5, Paolo Gisondi6, 
Luca Idolazzi7, Marisa Gariglio2,3, and Carlo Selmi4,8
1 Department of Public Health and Paediatric Sciences, Turin Medical School; 2 
Department of Translational Medicine, Novara Medical School; 3 Intrinsic Immunity 
Unit, CAAD - Center for Translational Research on Autoimmune and Allergic Diseases, 
University of Piemonte Orientale, Novara; 4 Rheumatology and Clinical Immunology 
Unit, Humanitas Research Hospital, Rozzano; 5 Rheumatology, University of Siena; 6 
Dermatology, University of Verona; 7 Rheumatology, University of Verona; 8 
Department of Biomedical Science and Translational Medicine, University of Milan, 
Italy.
Corresponding author: Carlo Selmi MD PhD, Division of Rheumatology and Clinical 
Immunology, Humanitas Research Hospital, via A. Manzoni 56, 20089 Rozzano, 
Milan, Italy; tel +39-02-8224-5129, fax +39-02-8224-2298, email carlo.selmi@unimi.it































































Key words: IFI16; anti-IFI16 antibodies; psoriatic arthritis 
List of abbreviations:
interferon-inducible protein 16 (IFI16) 
psoriatic arthritis (PsA)
psoriasis (Pso) 
C-reactive protein (CRP) 
rheumatoid arthritis (RA), 
tumor necrosis factor-α (TNF-α)
interleukin(IL)
interferon (IFN) 
plasmacytoid dendritic cells (pDC) 
immunofluorescence (IIF) 
immunoprecipitation (IP) 
protein A sepharose (PAS) 
sodium dodecyl sulphate- polyacrylamide (SDS-PAGE)
human foreskin fibroblast (HFF)
horseradish peroxidase (HRP)
phosphate buffered saline (PBS)
disease activity score (DAS) 
systemic lupus erythematosus (SLE)
































































Objective. The nuclear interferon-inducible protein 16 (IFI16) and anti-IFI16 antibodies 
have been detected in subjects with several rheumatic diseases, often correlating with 
disease severity, and we herein investigated their prevalence and clinical associations in 
psoriatic arthritis (PsA) compared to psoriasis (Pso). 
Methods. We tested sera and synovial fluids of patients with PsA for IFI16 protein 
levels by capture ELISA and for anti-IFI16 IgG and IgA by ELISA, protein radio-
immunoprecipitation and immunoprecipitation-Western blot of IgG. Sera from patients 
with Pso and healthy subjects were used as controls, and in a subgroup of patients with 
PsA we also studied sera after treatment with etanercept. 
Results. IFI16 was detectable in the sera of 66% of patients with Pso, 46% of PsA, and 
19% of controls. Among PsA cases, 51% of IFI16-positive cases had elevated levels of 
C-reactive protein (CRP) compared to 31% of patients with undetectable IFI16. Anti-
IFI16 of both IgG and IgA isoforms were detected with significantly higher frequency 
in PsA and Pso compared to healthy controls, with higher IgG titers in patients with 
elevated CRP (p=0.015) and a significant reduction in the majority of patients after 3 
month of etanercept treatment. Immunoprecipitation confirmed the presence of anti-
IFI16 IgG antibodies and these recognized the HINA epitope predominantly (amino 
acids 131 to 337). Lastly, IFI16 was detected in 1/7 and anti-IFI16 in 3/7 synovial fluids 
from patients with PsA. 
Conclusion. IFI16 and anti-IFI16 seem to be associated with higher disease activity and 
with treatment response in PsA. The detectability of these markers also in synovial 
fluids represents a novel finding with potential clinical implications.































































Psoriatic arthritis (PsA) is a chronic inflammatory disease within the broader psoriatic 
disease encompassing musculoskeletal features (with enthesitis, synovitis and erosion 
with osteitis of the peripheral joints and/or the axial skeleton), skin and nail 
manifestations [1], estimated to affect approximately 0.5% of the general population [2]. 
PsA is found in a variable proportion (15-40%) of the patients with psoriasis (Pso), and 
in 74% of cases it is preceded by skin manifestations [3]. 
Different from rheumatoid arthritis (RA), both PsA and Pso lack serum biomarkers for 
an early diagnosis, while sharing a T cell-mediated response based on the tumor 
necrosis factor-α (TNF-α)/interleukin(IL)-17 axis [4]. As reported for other immune-
mediated diseases [5], an interferon (IFN) signature is observed in Pso as self-DNA-
engulfed plasmacytoid dendritic cells (pDC) produce a large amount of IFN-α [6]. 
Further, an overexpression of IFN-γ and TNF-α-inducible genes is observed in Pso 
plaques due to T cell and macrophage recruitment and activation [7]. Despite these 
observations, treatments targeting IFN-α or IFN-γ have proven ineffective in Pso, while 
TNF-α and IL12/23 or IL17 blockers lead to clear skin in a large proportion of patients 
[8, 9]. 
The interferon-inducible protein 16 (IFI16) is a  DNA sensor involved in the 
inflammasome-mediated defense against viral infections [10], that displays also pro-
inflammatory and anti-angiogenetic effects [11]. In the case of psoriatic disease, IFI16 
is overexpressed in the affected skin [12], in peripheral blood mononuclear cells, and 
synovial tissues [13, 14]. Previous studies have demonstrated that IFI16 is 
overexpressed in different connective tissue diseases and in RA [5], and anti-IFI16 
antibodies have been detected in systemic lupus erythematosus (SLE) [15], Sjӧgren’s 































































syndrome [16, 17], systemic sclerosis [18-20], inflammatory bowel diseases [21], and 
RA [22], possibly associated with disease severity and progression. 
We report herein for the first time that IFI16 and anti-IFI16 antibodies are detectable in 
the sera and synovial fluids of patients with PsA and may represent disease activity 
biomarkers.

































































We investigated 158 consecutive patients with a diagnosis of PsA based on the 
CASPAR criteria [23] (Table 1), while 182 healthy subjects and 44 patients with skin 
or nail Pso but no evidence of PsA were used as controls. Serum samples were collected 
and stored at − 20°C until used; demographic and clinical data (presence or absence of 
psoriasis, presence or absence of axial involvement and reported blood tests done by the 
patient within one month) were recorded. DAS28 (disease activity score 28 joint) was 
available only for 30 PsA patients treated with biologic agents.  
In a subgroup of 8 patients with PsA, serum samples were also available at 3 months 
after starting weekly subcutaneously etanercept 50 mg. Synovial fluid samples from 7 
patients with PsA who underwent arthrocentesis for knee effusion and had not received 
intra-articular medications (e.g., corticosteroids, hyaluronic acid) in the previous 6 
months, were also analyzed (blood samples were collected on the same day). Synovial 
fluids were centrifuged and supernatants stored at − 80°C until use. Clinical and 
serologic records were collected at the time of enrollment. This study was approved by 
the local IRB and written informed consents were obtained from patients and controls.
Determination of extracellular IFI16 protein by capture ELISA 
A capture ELISA was employed for determination of circulating extracellular IFI16 
protein following a procedure described elsewhere [24], and the threshold cut-off value 
was defined as the 95th percentile of healthy controls as 27 ng/ml.
Determination of antibody titers toward human recombinant IFI16 by ELISA
To determine anti-IFI16 antibody titers of IgG and IgA isotype in sera of patients, we 































































performed in-house ELISA as previously described [21]. Accordingly, cut-off values 
were calculated as the 95th percentile of healthy controls and the threshold values were 
set to 113 U/ml and 9.6 U/ml for IgG and IgA isotype, respectively.
Indirect immunofluorescence assay
The localization of cellular antigens recognized by autoantibodies was tested by indirect 
immunofluorescence (IIF) on HEp-2 cells (INOVA Diagnostics, San Diego, CA, USA) 
using a 1:80 dilution of human sera of patients and controls, followed by secondary 
antibodies marked with fluorochrome (AlexaFluor488 AffiniPure F(ab')2 fragment goat 
anti-human IgG, Fcγ fragment specific, Jackson Immunoresearch Europe Ltd, Suffolk, 
UK) as previously described [25]. Samples were acquired on Olympus BX53 Upright 
fluorescence microscope.
Radioimmunoprecipitation assay
PsA sera were analyzed by protein radio-immunoprecipitation (IP) using marked 35S- 
HeLa cell extract. IP was used to identify autoantibodies directed against protein self-
antigens as described elsewhere [26]; briefly, sera were incubated with Protein A 
sepharose (PAS) beads and after serial washes samples have been incubated with cell 
lysate (radioactively marked for protein-IP). After forming immuno-complexes, 
samples were prepared for 8% sodium dodecyl sulphate- polyacrylamide (SDS-PAGE) 
electrophoresis for protein-IP. To confirm data obtained with IP we performed IP-
Western blotting. In detail, human sera and 50ng of mouse monoclonal anti-human 
IFI16 as a positive control were cross-linked with PAS beads to isolate human IgG 
directed against IFI16 [27]. IP was initially performed with cell extract from 5x106 
HeLa cells/sample, but since human foreskin fibroblast (HFF) express IFI16 at higher 































































basal levels than HeLa, control experiment was performed with HFF. Proteins were 
then fractionated by 8% SDS-PAGE and transferred to a nitrocellulose membrane, 
probed with 1:500 of mouse monoclonal anti-human IFI16 antibody (Novus 
Biologicals, Littleton, CO, USA) for band 88 kDa identification, followed by 
horseradish peroxidase (HRP)-goat anti-mouse IgG (1: 10000 dilution; ThermoFisher, 
Waltham, MA, USA). Development was performed by Immobilon Western 
Chemiluminescent HRP substrate (Millipore, Darmstadt, Germany) and acquired using 
ChemiDoc (Bio-Rad, California, USA).
Recombinant IFI16 domains
The coding region of the three IFI16 domains was amplified from full length human 
IFI16 (isoform b) cDNA using primers containing BamHI and XhoI restriction sites 
(DAPIN: Fw 5’ GGCGGATCCATGGGAAAAAAATACAAGAAC 3’; Rw 5’ 
GCCTCGAGTCATTTTAACTTTTCTTTTTTAAG 3’; HIN A: Fw 5’ 
GGCGGATCCCCGAAAACAGTGGCCAAATG 3’; Rw 5’ 
GCCTCGAGTCATTTCTTTATCTGGATAAAACTA 3’; HIN B: Fw 5’ 
GGCGGATCCGAACCTGAAGAAGTTTCCATA 3’; Rw 5’ 
GCCTCGAGTCAGATGACCTTGATGTGACTATG 3’). The amplified inserts were 
digested with BamHI and XhoI, and cloned in pET30a expression vector containing an 
N-terminal histidine tag (Novagen, Madison, WI). Expression and affinity purification 
of the recombinant proteins were performed according to standard procedures, and 
purity assessed by 12% SDS-PAGE gel electrophoresis.
IFI16 epitope mapping































































IFI16 protein domains were diluted in phosphate buffered saline (PBS) to a 
concentration of 2 ug/ml. Polystyrene microwell plates (Nunc-Immuno Maxisorp) 
(Thermo Scientific, Nunc, Roskilde, Denmark) were coated with 100 µl diluted protein 
per well, and incubated overnight at 4°C. After blocking, sera were added in duplicate. 
After washing, horseradish peroxidase-conjugated rabbit anti-human IgG 
(DakoCytomation) was added. Following the addition of the substrate 
(tetramethylbenzidine, KPL), absorbance was measured at 450 nm using a microplate 
reader (SpectraCount,Packard BioScience). The background reactivity of the reference 
mixture was subtracted to calculate the results. 
Statistical analysis
All data analyses were performed using Stata for Macintosh 13.1 (StataCorp, College 
Station, Tx, USA). As detailed throughout, chi-square test, Mann-Whitney U test, 
Kruskal-Wallis test with Dunn's test for multiple comparison post hoc, or Wilcoxon test 
were employed to compare groups based on the data distribution. Linear regression and 
Spearman’s test were used to correlate IFI16 and anti-IFI16 levels with continuous 
variables such as disease duration and age. C reactive protein (CRP) levels were 
reported for patients who had available blood tests within one months, the absolute 
values were not comparable due to different cut-offs between laboratories, therefore, we 
used the single cut-off of each center to discriminate high CRP levels.   
 Multivariate analysis adjusted for demographic and clinical data (age, sex and disease 
duration) was also performed. All comparisons were two-tailed and P values below 0.05 
were considered statistically significant.
































































Circulating IFI16 in different disease groups.
The levels of IFI16 were significantly higher in PsA and Pso patients compared to 
healthy controls (PsA median 0, range 0-131 versus healthy controls 0, 0-67.6, 
p=0.0004; Pso 7.93, 0-223.5 versus healthy controls p<0.0001; figure 1A). Moreover, 
IFI16 concentrations were higher in Pso patients compared to PsA (p=0.0006). 
According to the established 27 ng/ml threshold, 23/158 (15%) of PsA and 8/44 (18%) 
Pso sera were positive for circulating IFI16, compared to 6/116 (5%) healthy controls 
(PsA versus healthy controls p=0.002; Pso versus healthy controls p=0.003), confirming 
a higher prevalence of free IFI16 circulating protein in PsA and Pso patients in 
comparison with healthy controls.
Circulating IFI16 and PsA clinical features at baseline.
The clinical features of the PsA cases included disease duration, peripheral or axial 
involvement, and skin disease were analyzed according to the positivity/negativity for 
IFI16 protein are illustrated in Table 1. We identified a significant association between 
elevated CRP levels and the presence of the circulating IFI16 protein (p<0.0001). We 
subsequently evaluated whether IFI16 serum concentration, rather than its presence, 
could be correlated to any clinical variable. As expected, IFI16 levels were significantly 
higher in PsA cases with high CRP levels (median 23.5ng/mL, interquartile range (IQR) 
10.4-65.4) compared with patients with low CRP levels (2.6 ng/mL, IQR 1.4-10.6; 
p<0.001). IFI16 levels were also higher in PsA cases with Pso compared with patients 
without skin disease, albeit not significantly (11.4 ng/ml, IQR 2.6-31.9 vs. 6.4 ng/ml, 
IQR 1.8-67.6). No differences in IFI16 levels were observed with regard to ongoing 































































therapies. We further performed a multivariate analysis with pre-specified confounders 
and this failed to identify statistically significant differences after adjustment for age, sex 
and disease duration. 
Circulating IFI16 and PsA response to etanercept.
Samples at 3 months of etanercept treatment were also available for 8 subjects positive 
for IFI16 at baseline and we could observe a decrease in IFI16 levels in 5/8 patients 
(baseline median 81.7 ng/ml, IQR 63.2-102.1 vs. 31.8 ng/ml, 22.1-85 at 3 months; 
p=0.16). Similarly, according to DAS28-CRP, disease activity reached a minimal 
clinically significant reduction in 4/8 IFI16 positive patients, with a median reduction of 
1.25 points. Lastly, circulating IFI16 was measured in the synovial fluid of 7 PsA 
patients and detected in one case at low concentration (data not shown).
Circulating anti-IFI16 IgG and IgA and PsA clinical features at baseline.
Significantly higher levels of anti-IFI16 IgG antibodies were present in PsA and Pso 
patients in comparison with healthy controls (PsA median 96, IQR 65.3-151.7 versus 
healthy controls 28.9, IQR 17.3-45.3, p<0.001; Pso 94.9, 62.8-126 versus healthy 
controls, p<0.001), while the titers were comparable between PsA and Pso sera. 
According to the cut-off value of 113 U/ml, 57/158 (36%) PsA and 14/44 (32%) Pso 
sera were positive for anti-IFI16 IgG, compared to 11/182 (6%) of the healthy controls 
(p<0,001 versus PsA; p<0.001 versus Pso; Figure 1B).
When the autoantibody status was analyzed according to sex, age, disease duration, 
skin, axial involvement, or ongoing therapy (Table 1), we observed a significant 
correlation between anti-IFI16 IgG levels and disease duration after adjusting for age 































































(beta coefficient 0.38; p=0.036). Moreover, by considering anti-IFI16 IgG serum 
concentrations, anti-IFI16 IgG titers were increased in subjects with high CRP levels 
compared with subjects with low CRP levels (median 268.1 U/ml, IQR 162.8-562.4 
versus 162 U/ml, 142.1-199.7; p=0.015). However, there were no differences in the 
percentage of patients with high CRP and anti-IFI16 positive versus negative subjects 
(Table 1).  
Circulating anti-IFI16 IgG and IgA in different disease groups.
Median anti-IFI16 IgA titers were increased in PsA and Pso sera compared to healthy 
controls (PsA 4.7, IQR 3.3-7.1 versus healthy controls 3.7, 2.5-5.2, p<0.0001; Pso 7.4, 
0-16.5 versus healthy controls p<0.0001); moreover, anti-IFI16 IgA were higher in Pso 
compared to PsA sera (p<0.0001). According to the 9.6 U/ml threshold, 25/158 (16%) 
of PsA and 16/44 (36%) of Pso sera were positive, compared to 7/138 (5%) of healthy 
controls (p<0.001 versus PsA; p<0.001 versus Pso; p=0.004 PsA versus Pso) (Figure 
1C). As reported in Table 1, anti-IFI16 IgA positive PsA cases were significantly older 
compared to anti-IFI16 IgA negative (median age 63.5, IQR 49-69 vs 48.5, IQR 42-58; 
p<0.001).  
Circulating anti-IFI16 IgG and IgA and PsA response to etanercept.
Six subjects positive for anti-IFI16 IgG at baseline were tested also during etanercept 
therapy without significant changes in autoantibody titers after 3 months of therapy 
(baseline median 197 U/ml, IQR 188-269 versus 3months 223 U/ml, 194-269; p=0.9). 
Of these, 4/6 (67%) did not reach a minimal clinically significant reduction of DAS28-
CRP and the median DAS28 change was -0.85 after 3 months of therapy. Four subjects 































































positive for anti-IFI16 IgA were subsequently tested after 3 months of etanercept 
therapy without significant changes in antibody titers (basal median 7.56, IQR 5.18, 
12.72 versus 3 months 6.55, 5.46-12.6; p=0.2), while 3/4 (75%) of these reached a 
minimal clinically significant reduction of DAS28, with a median DAS28 change of -
2.25 (data not shown). 
Synovial fluid anti-IFI16 IgG and IgA and PsA clinical features.
Anti-IFI16 IgG and IgA antibodies were measured also in synovial fluids of 7 PsA 
patients (data not shown). Three out of 7 samples were positive for IgG subtype and 2/7 
were positive for IgA subtype, and only 1 patient was positive for both Ig subtypes. We 
failed to detect correlation between antibody titers and any of the clinical parameters 
analyzed. 
Anti-IFI16 confirmation tests
Protein-IP and IP-WB were used to confirm the presence of anti-IFI16 IgG antibodies, 
as these techniques are considered the gold standard for the identification of 
autoantibodies thanks to their high sensitivity and specificity. As shown in Figure 2A, 
we performed protein-IP on 19 cases and we identified an IP pattern of PsA sera 
recognizing a 90 kDa protein (black arrows, Figure 2A). This band corresponds to the 
IFI16 protein as shown by IP-WB (Figure 2B). IIF was also performed to localize the 
IFI16 antigenic target, and we could confirm it is present in the nucleus according the 
its nuclear function (Figure 2C).  
Circulating IFI16 and anti-IFI16 IgG and IgA in the study populations.































































When IFI16 and anti-IFI16 data were combined, no correlations were found between 
IFI16 and anti-IFI16 IgG or IgA levels. However, we note that among the 57 PsA 
patients positive for anti-IFI16 IgG, 13 (23%) were positive also for circulating IFI16. 
In contrast, 57% of the 23 patients positive for IFI16 were also positive for IgG 
autoantibodies (Table 2). Among the 25 PsA patients positive for anti-IFI16 IgA, 5 
(20%) were positive for the circulating protein. A significant correlation between anti-
IFI16 IgG and IgA antibody titers was observed in PsA (Spearman’s r=0.1802, 
p=0.0235). Moreover, while only 21% of the 57 PsA patients positive for anti-IFI16 
IgG were positive also for the IgA subtype, 48% of 25 IgA positive patients displayed 
also high titers of anti-IFI16 IgG antibodies.
 Anti-IFI16 IgG epitope mapping
To determine whether anti-IFI16 IgG antibodies detected in sera were directed against 
specific IFI16 domains, we cloned the DAPIN (spanning from aa 1 to 88), HINA (from 
aa 131 to 337) and HINB (from aa 506 to 705) domains of IFI16 in a pET30a 
expression vector. The purity and specificity of the recombinant domains were then 
established by blue Comassie and Western blot analyses, and finally recombinant 
DAPIN (rDAPIN), rHINA and rHINB were used as immobilized surface in ELISA for 
testing the sera of the 57 patients positive for anti-IFI16 IgG. As shown in Figure 3, the 
serum samples displayed a strong reactivity against the HIN domains. Regardless of 
their aminoacid homology (44%), HINA was better recognized in comparison with 
HINB domain by disease and control sera. In contrast, the DAPIN domain, which is the 
moiety of the protein mainly involved in inflammatory activity, was poorly detected by 































































autoantibodies, suggesting that anti-IFI16 IgGs are mainly directed against an epitope 
outside the N-terminus of the protein. 
































































A significant role of DNA sensing peptides in the pathogenesis of Pso has been recently 
suggested, largely based on data about LL37, a fragment of the anti-microbial protein 
cathelicidin, capable to activate dendritic cells by complexing self-DNA, and T cells by 
acting as a self-antigen [28, 29]. Similar to other autoimmune diseases characterized by 
serum reactivity to intracellular antigens we cannot speculate on the pathogenetic 
mechanisms linking IFI16 autoantibodies to tissue damage. However, we suggest that 
the DNA sensor IFI16 is involved as a self-antigen in the humoral response and in the 
inflammatory response possibly via the inflammasome in PsA. 
In the present study, we observed that IFI16 and anti-IFI16 seem to be associated with 
higher disease activity in PsA and possibly with response to anti-TNFalpha treatment, 
thus possibly being candidate biomarkers of this seronegative condition and 
representing a different clinical phenotype. Furthermore, these markers are detected also 
in the synovial fluids for the first time and may thus represent a mechanistic player in 
the PsA pathogenesis. These findings may be promising in filling the diagnostic gap of 
PsA where no serum biomarker for the diagnosis or management is available [30].
IFI16 is an interferon-induced protein and a DNA sensor able to start an innate immune 
response against pathogenic microorganism by activating the inflammasome and the 
production of type I IFNs [31]. It has been proposed that the large amount of self-DNA 
secondary to keratinocyte proliferation in Pso plaques can activate pDC via LL37/TLR9 
to produce INF-α and recruit T cells and, at the same time, can activate the 
inflammasome with IL-1β production [31, 32]. The overexpression of IFI16 in 
keratinocytes could be explained by an attempt to control excessive cell proliferation, 
resulting, however, in a chronic activation of the inflammasome. Furthermore, 































































extracellular IFI16 can spread inflammation since it has been demonstrated that the 
protein is able to bind the membrane of endothelial cells and to induce the production of 
pro-inflammatory cytokines in these cells [24, 33]. The hypothesis based on an 
accelerated cell turnover seems to be supported by the high IFI16 levels observed in 
patients with Pso and in PsA with skin PsO and IFI16 overexpression in PsA circulating 
mononuclear cells and synovial tissue [13]. In fact, in PsA sera IFI16 is significantly 
higher compared to healthy controls, particularly when associated with an active disease 
represented by elevated CRP and mechanisms may include changes similar to what 
observed in systemic lupus erythematosus models [34] or NETosis in a self-
perpetuating fashion [35]. 
Type I IFN inducible genes are elevated in the serum of patients with different systemic 
autoimmune diseases, albeit with inconclusive evidence and frequently conflicting 
results in different rheumatic conditions [36]. IFI16 is among the five most important 
IFN inducible genes being overexpressed in connective tissue diseases and RA, raising 
the coined “IFN-signature” [5]. Different from PsA in which IFI16 significantly 
correlates with inflammation, this protein is not a biomarker of disease activity in RA, 
but is associated with pulmonary involvement and with the presence of rheumatoid 
factor and anti-cyclic citrullinated peptide antibodies. IFI16 in RA synovial fluid is not 
associated with joint disease activity, disease duration or erosion [22]. In the case of 
SLE, IFI16 is associated with disease activity, particularly lupus nephritis, and is found 
overexpressed in skin lesions [18, 37, 38]. 
The inflammatory context in which an intracellular protein is released is thought to be 
one of the mechanisms leading to the breakdown of tolerance and the recognition of 
self-antigens; this hypothesis could explain the antibody response against IFI16 































































observed in PsA and Pso, particularly with the intriguing observation of a prevalent IgA 
response compared to IgG response in PsO versus PsA. As previously mentioned and 
different from PsA (with anti-IFI16 IgG titers slightly increased in subjects with 
elevated CRP levels), anti-IFI16 antibodies are not correlated to RA activity, but rather 
with serum autoantibody positivity, while no association between anti-IFI16 and disease 
activity or erosions has been found [22]. In SLE, anti-IFI16 antibodies were first 
reported to be associated with anti-double stranded DNA antibodies [17, 18], but this 
was not confirmed by our group [15]. Anti-IFI16 antibodies positive patients with 
systemic sclerosis were more likely to have limited cutaneous systemic sclerosis, a 
longer disease duration and more severe vascular and pulmonary manifestations, i.e. 
digital ischemia and a low carbon monoxide diffusing capacity [18, 20]. An association 
with disease severity, as for PsA, has been documented in Sjӧgren’s syndrome, with 
lower tear and saliva production, higher focus score in minor salivary glands biopsies, 
germinal center-like structures in the labial salivary gland lymphocytic infiltrates, and 
higher IgG and antinuclear antibodies levels being associated with anti-IFI16 [16, 17]. 
The epitope mapping also provided somehow surprising evidence compared to other 
rheumatic conditions. In systemic sclerosis, anti-IFI16 reacted with either N- or C-
terminal fragments or both [18], while in 70% of Sjӧgren’s syndrome anti-IFI16 were 
directed against an epitope outside the N terminus [17] and in SLE antibodies are 
directed predominantly against N-terminus [17]. We can hypothesize that in SLE anti-
IFI16 blocking the N-terminus allows the formation of self-DNA/IFI16 complexes 
which favor nucleic acid clearance and are protective in terms of SLE nephritis. Our 
data in PsA are in agreement with those obtained in Sjӧgren’s syndrome, since the 































































DAPIN domain was poorly detected by anti-IFI16 IgG. Accordingly, this would have 
left free the moiety of the protein mainly involved in the inflammatory activity.
We are well aware of the limitations of our study, including the limited clinical data 
available but we report for the first time that IFI16 and anti-IFI16 are detectable in the 
sera of patients with PsA and seems to correlate with the degree of inflammation and 
possibly with treatment response. We cannot exclude a role of this protein and the 
elicited antibody in the pathogenesis of PsA; moreover, IFI16 and anti-IFI16 maybe 
represent new candidate biomarkers for PsA diagnosis and monitoring when data 
confirmed in larger and longitudinal studies. 
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Figure 1. Serum IFI16 and anti-IFI16 IgG and IgA levels in patients with PsA, 
Psoriasis and HCs. (A) IFI16 protein levels in patients’ and controls’ sera were 
determined using an in-house capture ELISA. Each dot represents the concentration of 
IFI16 protein (expressed in ng/ml on a linear scale) in each individual subject. The 
horizontal bar represents the median values. Values over the dotted line indicate the 
percentage of subjects with IFI16 protein levels above the cut-off value (27 ng/ml). (B) 
Serum IgG and (C) IgA specific for IFI16 were quantified by ELISA in HC and patients 
suffering from psoriatic arthritis and psoriasis. Each dot represents the autoantibody 
level for each subject sample expressed in arbitrary units on a linear scale. The 
horizontal bars in each group represent the median values. Values over the dotted line 
indicate the percentage of subjects with antibody titers above the cutoff value (113 
U/mL for anti-IFI16 IgG and 9.6 U/mL for anti-IFI16 IgA, calculated as the 95th 
percentile of the control population). Statistical significance: ***p < 0.0001 (Mann–
Whitney tests).
Figure 2. Analysis of protein component of autoantigen IFI16 (8% SDS-PAGE) by 
radio-immunoprecipitation (IP) (A) and IP-Western Blotting (WB) (B), and 
indirect immunofluorescence (C). The IP pattern of PsA sera recognizing a 90 kDa 
protein (black arrows, 2A). IP-WB confirming the identity of the IP bands 
corresponding to IFI16 (2B). The expected ANA pattern for a representative sample 
positive for ani-IFI16 IgG (2C).































































Figure 3. Epitope mapping for anti-IFI16 IgG. To determine the target of the anti-
IFI16 IgG antibodies found in the sera of PsA patients, the DAPIN (spanning from aa 1 
to 88), HINA (from aa 131 to 337) and HINB (from aa 506 to 705) domains of IFI16 
were purified as recombinant peptides and 2ug/mL each used to perform ELISA. Each 
dot represents the value of the absorbance at 450nm for the 57 sera tested against the 
three domains. The horizontal bars in each group represent the median values. Statistical 
significance: ***p < 0.0001 (Mann–Whitney tests). Panel A shows PsA patients and 
panel B healthy controls.
































































Table 1. Demographic, clinical and serological characteristics of PsA patients.
 
 IFI16 Anti-IFI16 IgG Anti-IFI16 IgA
All PsA Positive Negative Positive Negative Positive Negative
Patients (%) 158 (100) 23 (15) 135 (85) 57 (36) 101 (64) 26 (17) 132 (83)
Women (%) 93 (50.5) 12 (52) 67 (50) 34 (60) 45 (45) 11 (42) 68 (52)























76 (49) 14 (61) 62 (47) 33 (60) 43 (43) 14 (54) 62 (47)




45 (29) 7 (30) 38 (29) 16 (28) 29 (29) 4 (15) 41 (31)
High CRP (%) 63 (40) 18 (78) 45 (33)* 23 (40) 40 (40) 12 (46) 51 (39)
Ongoing 
treatments:
no treatment 64 (40.5) 17 (74) 77 (57) 21 (39) 43 (43) 9 (35) 55 (42)





















anti-TNFα 30 (19) 2 (9) 28 (21) 15 (26) 15 (15) 3 (12) 27 (20)
etanercept 8 1 7 4 4 1 7
adalimumab 2 0 2 1 1 0 2
infliximab 20 1 19 9 11 2 18
Continuous variables are expressed as median and IQR, binary as numbers and percentages. 
PsA: psoriatic arthritis; IFI16: interferon-inducible protein 16; Ig: immunoglobulin; yy: years; mm: 
months; Ig: immunoglobulin; CRP: C reactive protein; TNF: tumor necrosis factor. 
*p<0.01 positive vs. negative patients, ** p<0.001 positive vs. negative patients 































































Table 2. Association of IFI16-based biomarkers in the PsA cohort.

















5/23 (22%) 12/57 (21%) -
Variables are expressed as numbers (n) and percentages. 
PsA: psoriatic arthritis; IFI16: interferon-inducible protein 16; Ig: immunoglobulin.
 *p<0.01, ** p<0.001
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